Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Serlopitant (Primary)
  • Indications Prurigo nodularis; Pruritus
  • Focus Registrational; Therapeutic Use
  • Sponsors Menlo Therapeutics
  • Most Recent Events

    • 29 Oct 2019 According to an Menlo Therapeutics media release, the company expects results from the PN trials in March or April of 2020. If these trials are successful,the company plans to submit an NDA for pruritus associated with PN in the second half of 2020.
    • 29 Oct 2019 Status changed from recruiting to active, no longer recruiting, according to an Menlo Therapeutics media release.
    • 06 May 2019 Planned number of patients changed from 200 to 280.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top